| Date | Title | Description | |
|---|---|---|---|
| 07 Nov 2024 | On P&L | The Company releases the press release related to the first nine months 2024 financial results | Download |
| 07 Nov 2024 | On P&L | The Company releases the first nine months 2024 financial results presentation | Download |
| 24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
| 31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
| 31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 07 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 04 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
| 28 Jul 2021 | On business and financial situation | The company releases the press release related to first half 2021 financial results | Download |
| 28 Jul 2021 | On business and financial situation | ROVI releases the first half 2021 results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
| 21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
| 24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |